During this segment, Richard W. Joseph, MD, describes the effectiveness of the anti-PD-1 agents pembrolizumab and nivolumab, and discusses similarities and differences between the 2 drugs.
Dr Joseph explains that although no head-to-head trials have directly compared the 2 agents, cross-trial comparisons have demonstrated that they are similar in terms of safety and efficacy. For this reason, he questions why the FDA approved pembrolizumab after just a phase 1 study but required a phase 3 study prior to approving nivolumab.
One difference between the 2 drugs, he notes, is that while nivolumab is administered every 2 weeks, pembrolizumab is given every 3 weeks.
Dr Joseph suggests that unless proved otherwise, the agents should be considered equivalent by managed care organizations and payer coverage should be the same for both drugs.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen